论文部分内容阅读
目的探讨依达拉奉联合奥扎格雷钠治疗急性脑梗死临床效果及安全性。方法选取本院神经内科2011年5月至2012年12月收治急性脑梗死患者120例,随机分为对照组和观察组,其中对照组患者60例,给予奥扎格雷钠50mg/次,2次/d静脉滴注-治疗;观察组患者60例,在对照组治疗基础上,加用依达拉奉80mg/次,2次/d静脉滴注治疗;比较两组患者临床治疗总有效率、治疗前后神经功能缺损评分(NIHSS)和日常生活能力(ADL)评分及毒副作用发生情况等。结果观察组患者临床治疗总有效率明显高于对照组,组间比较差异具有统计学意义(P<0.05);对照组与观察组患者治疗前NIHSS评分组间比较差异无统计学意义(P>0.05);两组患者治疗后NIHSS评分较治疗前明显下降,且观察组患者下降程度明显高于对照组,组间比较差异具有统计学意义(P<0.05);对照组与观察组患者治疗前ADL评分组间比较差异无统计学意义(P>0.05);两组患者治疗后日常生活能力评分较治疗前明显提高,且观察组患者提高程度明显优于对照组,组间比较差异具有统计学意义(P<0.05);两组患者毒副作用发生率组间比较差异无统计学意义(P>0.05)。结论依达拉奉联合奥扎格雷钠治疗急性脑梗死能够有效改善临床症状,促进受损神经功能恢复,提高日常生活能力,且无严重毒副作用。
Objective To investigate the clinical efficacy and safety of edaravone combined with ozagrel sodium in the treatment of acute cerebral infarction. Methods A total of 120 patients with acute cerebral infarction who were admitted to Department of Neurology from May 2011 to December 2012 in our hospital were randomly divided into control group and observation group, in which 60 patients in control group were given sodium ozagrel 50 mg twice daily, / d intravenous infusion - treatment; observation group of 60 patients on the basis of the control group, plus edaravone 80mg / times, 2 times / d intravenous infusion; comparison of the two groups of patients with total effective rate of clinical treatment, Neurological deficit score (NIHSS) and daily living ability (ADL) score and the occurrence of toxic and side effects before and after treatment. Results The total effective rate of clinical treatment in the observation group was significantly higher than that in the control group, with significant difference between the two groups (P <0.05). There was no significant difference between the NIHSS scores in the control group and the observation group before treatment (P> 0.05). NIHSS score decreased significantly after treatment in both groups, and the degree of decline in the observation group was significantly higher than that in the control group (P <0.05). The control group and observation group before treatment There was no significant difference in ADL score between the two groups (P> 0.05). After treatment, the daily living ability scores of both groups were significantly increased, and the improvement in the observation group was significantly better than that in the control group. The difference between the two groups was statistically significant (P <0.05). There was no significant difference between the two groups in the incidence of side effects (P> 0.05). Conclusion Edaravone combined with ozagrel sodium in the treatment of acute cerebral infarction can effectively improve the clinical symptoms, promote the recovery of damaged nerve function and improve the ability of daily living without serious side effects.